A Clinical Study With MT-102 in Subjects With Cancer Cachexia

Summary

A phase II clinical study to evaluate MT-102 administered over a sixteen week period in subjects with cachexia related to non-small cell lung cancer and colorectal cancer

Timeline

Start

2011-04

Primary completion

2013-05

Completion

2013-05

Outcome

Met primary endpoint

release “The ACT-ONE Phase IIa trial met its primary endpoint with a statistically significant difference of absolute weight change over 16 weeks” actimedtherapeutics.com ↗

Drugs

Indications

No indication recorded.